

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases. Among its major competitors, Cymabay Therapeutics is ranked in 5th place for NPS while Biogen is 1st, and Athersys is 2nd.Their current market cap is $932.71M